Dashboard
1
With a fall in Net Sales of -14.48%, the company declared Very Negative results in Mar 26
- ROCE(HY) Lowest at 15.12%
- INTEREST COVERAGE RATIO(Q) Lowest at 895.12
- RAW MATERIAL COST(Y) Grown by 7.5% (YoY)
2
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,528 Million (Mid Cap)
12.00
NA
3.24%
-0.02
14.80%
1.68
Revenue and Profits:
Net Sales:
692 Million
(Quarterly Results - Jun 2026)
Net Profit:
101 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.06%
0%
4.06%
6 Months
-20.82%
0%
-20.82%
1 Year
-37.62%
0%
-37.62%
2 Years
-42.77%
0%
-42.77%
3 Years
-50.82%
0%
-50.82%
4 Years
-38.51%
0%
-38.51%
5 Years
-61.57%
0%
-61.57%
Hunan Jiudian Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
22.56%
EBIT Growth (5y)
29.99%
EBIT to Interest (avg)
23.09
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.17
Sales to Capital Employed (avg)
1.03
Tax Ratio
10.20%
Dividend Payout Ratio
41.79%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
20.98%
ROE (avg)
18.06%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.77
EV to EBIT
10.93
EV to EBITDA
8.92
EV to Capital Employed
1.78
EV to Sales
1.56
PEG Ratio
NA
Dividend Yield
3.08%
ROCE (Latest)
16.29%
ROE (Latest)
14.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
691.60
815.90
-15.23%
Operating Profit (PBDIT) excl Other Income
166.50
204.30
-18.50%
Interest
8.20
3.30
148.48%
Exceptional Items
0.00
0.00
Consolidate Net Profit
100.80
165.60
-39.13%
Operating Profit Margin (Excl OI)
175.60%
215.20%
-3.96%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -15.23% vs 5.24% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -39.13% vs 4.48% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,087.50
2,910.00
6.10%
Operating Profit (PBDIT) excl Other Income
669.10
637.50
4.96%
Interest
15.20
18.70
-18.72%
Exceptional Items
0.00
0.00
Consolidate Net Profit
470.00
512.40
-8.27%
Operating Profit Margin (Excl OI)
175.90%
185.90%
-1.00%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 6.10% vs 9.02% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -8.27% vs 39.13% in Dec 2024
About Hunan Jiudian Pharmaceutical Co., Ltd. 
Hunan Jiudian Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






